Associate Director, Clinical Operations at Corcept Therapeutics

Redwood City, California, United States

Apply Now

Not SpecifiedCompensation

Mid-level (3 to 4 years)Experience Level

Full TimeJob Type

NoVisa

Pharmaceuticals, BiotechnologyIndustries

Requirements

Candidates should possess leadership skills to guide study teams and coordinate across multiple disciplines to achieve study goals and timelines. A strong management ability to lead staff toward common goals by providing guidance to subordinates and teams based on organizational goals and company policy is required. Detailed knowledge of clinical operations and regulatory requirements is also necessary.

Responsibilities

The Associate Director, Clinical Operations will provide expertise and oversight for multiple clinical trials or a clinical program, ensuring compliance with protocols, SOPs, GCP, and corporate goals. This role involves leading Clinical Operations teams in managing CROs and other vendors, contributing expertise in cross-functional meetings, and developing departmental policies and initiatives. Responsibilities include supervising study programs, contributing to study protocol development, reviewing informed consent forms, overseeing vendors, and providing performance feedback on CROs and clinical sites.

Skills

Clinical Operations

GCP

SOPs

Clinical Trial Management

Vendor Management

Cross-functional Collaboration

Study Management

Resource Allocation

Corcept Therapeutics

Develops cortisol modulators for medical conditions

About Corcept Therapeutics

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing various health issues. Their main product, Korlym, is used to treat Cushing's syndrome, a condition caused by too much cortisol. Korlym was approved by the FDA in 2012 and is the first medication specifically for this disorder. Corcept stands out from competitors by having a strong emphasis on research and development, having discovered over 1,000 unique cortisol modulators. The company aims to expand its range of treatments while also providing educational resources to healthcare professionals and patients to improve understanding and care for cortisol-related conditions.

Menlo Park, CaliforniaHeadquarters

1998Year Founded

$39.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Remote Work Options

Flexible Work Hours

Risks

Teva's antitrust lawsuit could lead to legal expenses and market share loss.

Heavy reliance on Korlym makes Corcept vulnerable to market fluctuations.

Recent investments may pressure Corcept for short-term financial performance, impacting R&D.

Differentiation

Corcept specializes in cortisol modulation, a niche with few direct competitors.

Korlym is the first FDA-approved treatment for Cushing's syndrome, a significant market advantage.

Corcept's extensive R&D has led to the discovery of over 1,000 selective cortisol modulators.

Upsides

Increased interest in cortisol therapies for mental health boosts Corcept's R&D prospects.

Advancements in drug delivery systems could enhance Corcept's product efficacy.

The FDA's fast-track designation supports Corcept's innovative cortisol-related treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free